PD-L2 protein levels in cancer cells and stroma cells were measured retrospectively by fluorescence-based immunohistochemical staining and quantitative image histocytometry in ER+ breast cancer specimens from a total of 684 patients using a validated immunohistochemistry protocol (Figs 1A-1F and Data Supplement). This evidence concerns the gene PDCD1LG2 and breast cancer.